In order to enhance the company's innovation ability and market competitiveness, and provide consumers with high-quality, safer, and more effective drugs, Zhengzhou RAAS Blood Products Co., Ltd. (hereinafter referred to as Zhengzhou RAAS), a wholly-owned subsidiary of Shanghai RAAS Blood Products, has been committed to optimizing the product process.

On December 31, 2020, the National Drug Administration accepted the supplementary application for process optimization of intravenous injection of human immunoglobulin (pH4) submitted by Zhengzhou RAAS (acceptance number: CYSB2000416). On September 9, 2021, we obtained the "Drug Supplementary Application Approval Notice" (Notice No. 2021B03194). From December 13th to 15th, 2021, the Audit and Inspection Center of Henan Food and Drug Administration conducted a compliance inspection on the resumption of production of human immunoglobulin for intravenous injection in Zhengzhou RAAS. Recently, the Zhengzhou RAAS intravenous injection human immunoglobulin production line officially resumed production.

The resumption of production of intravenous immunoglobulin is of great significance for Zhengzhou RAAS to increase revenue, expand market share, and achieve long-term development of the enterprise. In order to promote the smooth resumption of production of the products, Zhengzhou RAAS employees are diligent and dedicated, and have received strong support from Shanghai RAAS executives and technical teams in advancing the overall project schedule and technical aspects. At present, the projects of Zhengzhou RAAS coagulation factor products and special exemption products are steadily advancing.

Zhengzhou RAAS will continue to do a good job in quality management and brand management, with the mission of "people, career, and national sentiment", and create more social value.